AptaSure™ // aptamer diagnostics

Reading the molecular signature of resistance.

Invenio Medical builds rapid, point-of-care diagnostics on engineered aptamer chemistry. Our lead test detects the protein that defines MRSA — in about ten minutes, with no lab and no instrument.

AptaSure MRSA rapid point-of-care test device
TARGET // pbp2a FORMAT // gold-nanoparticle lateral flow READ // ~10 min, colorimetric COLD CHAIN // none
01 // The science

Two aptamers. One protein. Zero ambiguity.

Aptamers are short, synthetic nucleic-acid sequences that fold into precise shapes and bind a chosen target with antibody-like specificity — but chemically synthesized, so they're stable, reproducible, and inexpensive at scale.

AptaSure™ uses a cognate pair of aptamers, each carrying gold-nanoparticle signal, that lock onto the MRSA resistance protein pbp2a at two distinct sites. That two-point binding is what drives sensitivity and selectivity — and resolves to a simple colored line.

How the assay works
02 // The assay

From swab to readable line.

A single device runs the whole process — designed for the bedside, not the bench.

RESULT INTERPRETATION
C only  // negative
C + T  // positive
no C  // invalid
STEP // 01

Capture

A gold-nanoparticle–labeled aptamer binds the MRSA marker protein pbp2a in the nasal-swab sample.

STEP // 02

Confirm

A second, cognate aptamer binds pbp2a at a different site — a two-point lock that drives specificity.

STEP // 03

Read

The complex concentrates at the test line for a visible colorimetric result in minutes — no reader needed.

~10 min
Time to result
1 swab
Point-of-care workflow
Snap
Pre-measured buffer
No refrigeration
03 // Pipeline

A focused lead program, with a platform behind it.

The same aptamer chemistry is designed to extend to additional targets over time.

AptaSure™ MRSATARGET // pbp2a  ·  methicillin-resistant S. aureus
510(k) // verify status
Target #2TARGET // next candidate
IN DEVELOPMENT
Target #3TARGET // roadmap
RESEARCH
04 // Advisory board

Guided by a seasoned scientific & clinical board.

AptaSure™ is shaped by advisors with deep experience across diagnostics, surgery, emergency medicine, and national health leadership.

Scientific advisor

Dr. Robert Bohannon, PhD

A pioneer of lateral-flow and molecular diagnostics; Chief Scientific Officer at EKF Life Sciences (PhD, Baylor College of Medicine).

Scientific advisor

Dr. Chiu Wen-ta

Neurosurgeon and former Minister of Health and Welfare of Taiwan; former president of Taipei Medical University and an internationally recognized injury-prevention researcher.

Clinical advisor

Stanley Toy, Jr., MD

A highly regarded emergency physician and healthcare executive — CEO of Greater El Monte Community Hospital, with leadership across multiple Southern California facilities.

Clinical advisor

Dr. Roger Lee, MD

Chief Medical Officer with clinical affiliations at UCLA, bringing medical-leadership perspective to the AptaSure™ program. Name the organization?

05 // Leadership

Operators who know the clinic and the regulation.

VL

Dr. Victor R. Lange

Founder · President & CEO

PhD, JD, MSPH. Leads clinical, quality, and regulatory strategy and the AptaSure™ program.

KO

Kevin Ohler

Co-Founder · CFO

Leads finance and corporate operations, including financing and aptamer licensing.

JH
In memoriam · October 18, 2019

Jay Haischer

Co-Founder & COO

MHA, RPA-RT, VA-BC. A founding partner whose clinical insight and drive helped shape Invenio Medical. Remembered with gratitude.

06 // Investors

Following our progress?

Approved investors access company materials, regulatory updates, and financials in the secure portal.

Enter investor portal